GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier
You may also be interested in...
Wyeth's R&D pipeline is evolving the firm toward more specialized areas as several of its blockbuster products face patent expirations and generic challenges
FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25
GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City